Cancer treatment and the older patient.

In this issue of Clinical Cancer Research , Townsley et al. report the toxicities they observed in 401 patients enrolled on 19 phase I and II trials of targeted therapeutic agents as part of the National Cancer Institute's (NCI) early therapeutics development program ([1][1]). They compared